A
NBIX icon

AlphaQuest’s Neurocrine Biosciences NBIX Stock Holding History

AlphaQuest’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,576
Closed -$1.5M – 1313
2025
Q4 		$1.5M Sell
10,576
-2,573
-20% -$373K 0.08% 275
2025
Q3 		$1.85M Buy
13,149
+12,759
+3,272% +$1.73M 0.12% 206
2025
Q2 		$49K Sell
390
-1,005
-72% -$115K ﹤0.01% 1633
2025
Q1 		$154K Sell
1,395
-474
-25% -$60K 0.02% 1109
2024
Q4 		$255K Sell
1,869
-1,626
-47% -$201K 0.03% 773
2024
Q3 		$403K Buy
3,495
+3,044
+675% +$417K 0.04% 756
2024
Q2 		$62.1K Sell
451
-3,695
-89% -$507K 0.01% 1038
2024
Q1 		$572K Sell
4,146
-189
-4% -$25.8K 0.1% 332
2023
Q4 		$571K Buy
+4,335
New +$499K 0.12% 299

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaQuest's NBIX Position: Q1 2026 in Review

AlphaQuest sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 10,576 shares — an estimated $1.5M sold.

AlphaQuest first reported a position in NBIX in Q4 2023 and held it in 9 quarters. The position peaked at $1.85M in Q3 2025. 699 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • AlphaQuest reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 10,576 Neurocrine Biosciences shares in Q1 2026, an estimated $1.5M.
  • AlphaQuest first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 9 quarters.
  • AlphaQuest's Neurocrine Biosciences position peaked at $1.85M in Q3 2025.
  • 699 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.